secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2026-08-11T11:35:33+00:00
Accession:  0001855644-26-000007
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio completes enrollment in two Phase 2 tibulizumab trials; cash $205.1M
-----------------------------------------------------------------------------

- TibuSHIELD (hidradenitis suppurativa) enrolled 247 participants, exceeding target; topline data Q4 2026.
- TibuSURE (systemic sclerosis) enrolled 91 participants, exceeding target; topline data H1 2027.
- New indication: plans Phase 2 NEXUS-PMR for polymyalgia rheumatica by year-end 2026.
- Q2 2026 net loss $26.3M ($0.21/share) vs $16.0M ($0.17/share) in Q2 2025; R&D expenses $20.7M vs $8.7M.
- Cash and equivalents $205.1M expected to fund operations through at least end of 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/0001855644-26-000007-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000185564426000007/zura-20260811.htm
  HTML page:      https://secwatch.observer/filing/0001855644-26-000007

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer